BioLineRx holds annual shareholder meeting

• BioLineRx held its annual shareholder meeting on Sept. 23, 2026.
• Shareholders endorsed the reappointment of Dr. Aharon Schwartz, Dr. Sandra Panem, Dr. Shaoyu Yan as Class III directors through 2029.
• An increase in authorized share capital was adopted, including an amendment to the articles of association; implementation was not detailed.
• Equity-based awards for certain directors were authorized; issuance terms or timing were not specified.
• Kesselman & Kesselman (PwC member firm) was reappointed as independent auditor for the year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004591), on September 24, 2026, and is solely responsible for the information contained therein.